Search This Blog

Friday, August 09, 2013

The FDA and Gilead

We all know that Donald Rumsfeld served as the Chairman of the Board for Gilead 1997 to 2001. He moved on to become the Secretary of Defense under GW Bush. The U.S. later purchased 80 million doses of Tamiflu after GW Bush warned the country that a minimum of 200,000 people would die from avian flu but it could be as bad as two million deaths. In fact less than 100 people have been suspected of dying from this strain of the flu. See "The Great Bird Flu Hoax" by Dr. Joseph Mercola for more info on this one.

Today however, we have to talk about the latest collaboration between our government and Gilead. I'm just going to cut and paste this off of Biospace. It is too unbelievable to try and edit down.


WASHINGTON--(BUSINESS WIRE)-- AIDS Healthcare Foundation (AHF) won a key legal victory today in a push for drug safety as well as increased government transparency when a federal court ruled that the Food and Drug Administration (FDA) illegally blocked Freedom of Information Act (FOIA) requests tendered by AHF regarding correspondence between the FDA and Gilead Sciences. The description of the documents in the court ruling also implies collusion, suggesting the FDA worked with Gilead on what to say to get their unfavorable drug trial results spun in such a way that the FDA deemed them sufficient to approve the drug for expanded use of Truvada as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals. 

Ruling for the United States District Court, Central District of California (CV 11-07925 MMM [JEMx]), Judge Margaret M. Morrow ordered the FDA to disclose “…complete and unredacted copies of documents…” and correspondence between the FDA and Gilead regarding the safety and efficacy of PrEP as well as the drug company’s application to the FDA for approval of the use of Truvada as PrEP. 

“This ruling confirms one of our deepest suspicions: the FDA colluded with Gilead to fast-track approval of Truvada as PrEP regardless of the results of clinical trials. Judge Morrow’s ruling suggests the FDA advised Gilead how to conceal unfavorable clinical trial results and coached them on what to say to get those unfavorable results spun in such a way that the FDA deemed them sufficient to approve the drug,” said Michael Weinstein, AIDS Healthcare Foundation President. “All the while, the FDA was illegally denying our FOIA requests on this issue. Today’s ruling is a huge victory for increased government transparency, and one which will hamper the government’s ability to withhold information about a drug’s safety and efficacy.” 

In September 2011, AHF filed a lawsuit against the FDA over its denial of several AHF Freedom of Information Act requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to expand the use of Truvada for use as a form of pre-exposure prophylaxis. Despite concerns and complaints from AHF and other advocates and the pending FOIA lawsuit, the FDA approved Gilead’s application for use of Truvada as PrEP on July 16, 2012. 

“While the FDA is supposed to act as a neutral entity, the court ruling today confirms the FDA had private discussions with Gilead, and even fought on Gilead's behalf to withhold documents submitted to them by Gilead,” said Tom Myers, General Counsel and Chief of Public Affairs for AIDS Healthcare Foundation (AHF). “The lack of neutrality shown by the FDA here is breathtaking—further underscored in recent years by the fact that the FDA's budget for drug approval is now directly paid for by pharmaceutical companies such as Gilead.” 

Judge Morrow’s ruling suggests that the FDA worked together with Gilead to conceal unfavorable clinical trial results and used the very narrow FOIA privileges to conceal negative information. Citing a declaration of David J. Pizzuti, Gilead’s Vice President of Regulatory Affairs, the Court noted: 

“Pizzuti also reports that Gilead and the FDA discussed what datasets Gilead would submit in support of the Truvada for PrEP applications.54 In addition, he states, Gilead had discussions with the FDA regarding other studies conducted with Truvada that contained unfavorable results.55 Gilead and the FDA discussed how the safety and efficacy data proffered with Gilead’s supplemental NDA was nonetheless sufficient to support approval.56 Pizzuti reports that these discussions were memorialized in correspondence withheld by the FDA under Exemption 4,57and that disclosing the discussions would reveal how challenging PrEP study results can be successfully addressed, enabling competitors to craft successful PrEP applications that will cause Gilead competitive harm in the PrEP market.

_____________________________________________________________________________________________

We don't know who in the government is twisting the arms of the FDA leadership to get Gileads products approved and sold, but Gilead certainly has had a friend or two in high places. This story should be enough for a serious congressional inquiry on who what when and where. Remember that the FDA was formed after a large number of children died from Sulfa drugs. Safety was the issue. Clearly todays leaders in the FDA have failed to do their job. As Tom Meyers said, "The lack of neutrality shown by the FDA here is breathtaking-further underscored in recent years by the fact that the FDA's budget for drug approval is now directly paid for by pharmaceutical companies such as Gilead." This is more than a judicial issue one would think. It is time for the legislative branch to find out what happened and why. 

From the Cargo Cult perspective, we have to focus on the cherry picking of data and how it is done at the highest levels. 
Judge Morrow’s ruling suggests the FDA advised Gilead how to conceal unfavorable clinical trial results and coached them on what to say to get those unfavorable results spun in such a way that the FDA deemed them sufficient to approve the drug,” said Michael Weinstein, AIDS Healthcare Foundation President. 
This takes us back to the Ben Goldacre initiative to increase transparency in clinical trials. If this isn't a good reason to push for such legislation I don't know what is. Not only do we need greater access to ALL clinical trial data to help doctors, scientists and patients make sound medical decisions, we need to know if the FDA is advising the pharmaceutical company on how to hide data!




No comments: